Nick Galli is the founder of Alphina Therapeutics. Alphina Therapeutics has raised $40M in total funding. Latest round: Series A.
Nick Galli is the Chief Executive Officer at Alphina Therapeutics, a biotechnology company focused on developing a best-in-class NAMPT inhibitor for solid tumor indications. He also serves as a member of the company's board of directors. Alphina Therapeutics raised $40 million in a Series A financing in September 2021. Galli brings nearly two decades of experience in the pharmaceutical and biotechnology industry, with a background in strategy, company building, and business development.
Full founder directory · Investor directory · Company funding database · Fundraising library